Metformin use and prostate cancer risk: A meta-analysis of cohort studies

BACKGROUND: The relationship between metformin use and the risk of prostate cancer is still inconclusive. Therefore, we performed a systematic review and meta-analysis of all eligible cohort studies to evaluate a potential association of metformin use with prostate cancer risk. METHODS: A comprehens...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Zhaohan, Zhou, Xiaofeng, Liu, Naibo, Wang, Jianfeng, Chen, Xing, Xu, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709307/
https://www.ncbi.nlm.nih.gov/pubmed/30896668
http://dx.doi.org/10.1097/MD.0000000000014955
Descripción
Sumario:BACKGROUND: The relationship between metformin use and the risk of prostate cancer is still inconclusive. Therefore, we performed a systematic review and meta-analysis of all eligible cohort studies to evaluate a potential association of metformin use with prostate cancer risk. METHODS: A comprehensive literature search was performed in PubMed and Web of Science databases through July 2018. A DerSimonian and Laird random-effects model was applied to calculate the pooled relative risk (RR) and its 95% confidence interval (CI). RESULTS: Eighteen cohort or nested case-control studies were included in this study with a total of 52,328 cases. In a random-effect pooled analysis, metformin use was not significantly associated with the risk of prostate cancer (RR 0.97, 95% CI 0.80–1.16, P = .711). Statistically significant heterogeneity was identified among included studies (P < .001, I(2) = 98.1%). Sensitivity analysis indicated that no single study dominated the pooled RR. CONCLUSION: The present large meta-analysis of cohort studies did not find an association between metformin use and prostate cancer risk.

Ejemplares similares